van Creveldkliniek, Department of Haematology, Medical University Centre Utrecht, Utrecht, The Netherlands.
Blood Transfus. 2013 Jul;11(3):364-9. doi: 10.2450/2012.0092-12. Epub 2012 Nov 6.
Since the introduction of prophylaxis, physicians have tried to convert the clinical phenotype of severe haemophilia (SH) into that of moderate haemophilia (MH), but the outcome of patients with SH has never been compared to that of patients with MH.
The outcome of 80 patients with SH on long-term, intermediate dose prophylaxis was compared to that of 40 patients with MH in a single-centre study. Data on treatment history, activities (assessed by the IPAQ and HAL), quality of life (assessed by the SF-36 and EQ5D), and 5-year bleeding and clotting factor consumption were collected for patients born between 1970-1995.
The median age of the patients was 24 years (IQR 18-30). All patients with SH received long-term prophylaxis, which was started at a median age of 4.8 years (IQR 3.2-6.2). Among the patients with MH, ten (25%) received prophylaxis, starting at a median age of 10.8 years (IQR 3.8-13.8). The annual number of bleeds, including joint bleeds, was significantly higher in patients with SH (median 2.0 joint bleeds/year, IQR =0.8-3.7) than in patients with MH (median 0.8 joint bleeds/year, IQR =0-1.2). Due to greater use of prophylaxis, the annual clotting factor consumption of SH patients (median 2,120 IU/kg; IQR 1,514-2,768), was higher than that of MH patients (median 133 IU/kg; IQR 49-468). Patients with SH showed slightly but significantly more loss of clinical function (assessed by the Haemophilia Joint Health Score): a median of 8 points (IQR 3-15) vs a median of 2 points, IQR 0-6). Quality of life, as measured by the SF-36, EQ5D and physical activity, was similar between patients with disease of different severity, as well as compared to that of the general population.
When comparing unselected cohorts, the bleeding pattern of patients with SH does not appear to be fully converted to that of the milder bleeding pattern of MH by long-term, intermediate-dose prophylaxis, although activities and quality of life were similar.
自预防治疗引入以来,医生们一直试图将重型血友病(SH)的临床表型转化为中型血友病(MH),但从未对 SH 患者的预后与 MH 患者的预后进行比较。
在单中心研究中,我们比较了 80 名接受长期、中等剂量预防治疗的 SH 患者和 40 名 MH 患者的预后。收集了 1970-1995 年出生的患者的治疗史、活动(通过 IPAQ 和 HAL 评估)、生活质量(通过 SF-36 和 EQ5D 评估)和 5 年出血及凝血因子消耗数据。
患者的中位年龄为 24 岁(IQR 18-30)。所有 SH 患者均接受长期预防治疗,起始中位年龄为 4.8 岁(IQR 3.2-6.2)。10 名(25%)MH 患者接受了预防治疗,起始中位年龄为 10.8 岁(IQR 3.8-13.8)。SH 患者的年出血次数(包括关节出血)明显高于 MH 患者(中位 2.0 次关节出血/年,IQR =0.8-3.7)。由于更频繁地使用预防治疗,SH 患者的年凝血因子消耗(中位数 2120IU/kg;IQR 1514-2768)高于 MH 患者(中位数 133IU/kg;IQR 49-468)。SH 患者的临床功能丧失(通过血友病关节健康评分评估)略有但显著增加:中位数 8 分(IQR 3-15)vs 中位数 2 分,IQR 0-6)。SF-36、EQ5D 和身体活动评估的生活质量在不同严重程度的患者之间以及与一般人群相似。
在比较未选择的队列时,长期、中等剂量预防治疗似乎并未使 SH 患者的出血模式完全转化为 MH 较轻的出血模式,尽管活动和生活质量相似。